This is an application for competitive renewal of a grant to study control of expression of the atherogenic lipoprotein, lipoprotein(a) [Lp(a)]. Plasma levels of Lp(a) correlate generally with propensity for vascular diseases (myocardial infarction, re-stenosis, and stroke). The applicant proposes to utilize both in vitro and in vivo (transgenic model) approaches to delineate how the 1000-fold variation in plasma levels of Lp(a) in humans, which appears to be at least partially genetically determined, is accomplished. The applicant will examine the mechanism by which sex hormones and dietary fats may influence expression of Lp(a), principally by studying their interactions with polymorphic flanking sequences in the human apo(a) gene. The proposal consists of three Specific Aims. First, having already isolated 1400 base pairs of proximal promoter region, the investigators will clone additional upstream sequences in order to identify the hormone and cytokine response elements. Second, control of apo(a) expression will be assessed in vivo by constructing transgenic mice that harbor apo(a) constructs bearing or lacking specific control elements or regions. Third, the applicant will employ transgenic mouse models to test therapeutic modalities, such as estrogen and tamoxifen, which are designed to suppress expression of apo(a).

National Institute of Health (NIH)
National Heart, Lung, and Blood Institute (NHLBI)
Research Project (R01)
Project #
Application #
Study Section
Pathology A Study Section (PTHA)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Stanford University
Internal Medicine/Medicine
Schools of Medicine
United States
Zip Code
Krijgsveld, J; Zaat, S A; Meeldijk, J et al. (2000) Thrombocidins, microbicidal proteins from human blood platelets, are C-terminal deletion products of CXC chemokines. J Biol Chem 275:20374-81
Boffelli, D; Zajchowski, D A; Yang, Z et al. (1999) Estrogen modulation of apolipoprotein(a) expression. Identification of a regulatory element. J Biol Chem 274:15569-74
Ueda, Y; Royer, L; Gong, E et al. (1999) Lower plasma levels and accelerated clearance of high density lipoprotein (HDL) and non-HDL cholesterol in scavenger receptor class B type I transgenic mice. J Biol Chem 274:7165-71
Lou, X J; Boonmark, N W; Horrigan, F T et al. (1998) Fibrinogen deficiency reduces vascular accumulation of apolipoprotein(a) and development of atherosclerosis in apolipoprotein(a) transgenic mice. Proc Natl Acad Sci U S A 95:12591-5
Lawn, R M; Schwartz, K; Patthy, L (1997) Convergent evolution of apolipoprotein(a) in primates and hedgehog. Proc Natl Acad Sci U S A 94:11992-7
Hughes, S D; Lou, X J; Ighani, S et al. (1997) Lipoprotein(a) vascular accumulation in mice. In vivo analysis of the role of lysine binding sites using recombinant adenovirus. J Clin Invest 100:1493-500
Boonmark, N W; Lou, X J; Yang, Z J et al. (1997) Modification of apolipoprotein(a) lysine binding site reduces atherosclerosis in transgenic mice. J Clin Invest 100:558-64
Hughes, S D; Rubin, E M (1997) Vascular accumulation of Lp(a): in vivo analysis of the role of lysine-binding sites using recombinant adenovirus. Clin Genet 52:361-6